BioInvent International AB
↗Lund, Sweden
BioInvent International AB is a clinical-stage biotechnology company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer therapy. The company utilizes its proprietary F.I.R.S.T™ technology platform and n-CoDeR® antibody library to identify and develop candidates for hematological cancers and solid tumors.
Beyond its internal R&D pipeline, BioInvent operates a fully integrated manufacturing unit that produces antibodies for its own clinical trials and for external partners. The company maintains a strong focus on strategic collaborations with top-tier pharmaceutical companies to maximize the value of its assets.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$20M-$30M
Founded:1996
Ownership:public
Status:operating
FUNDING
Investors:The Leukemia & Lymphoma Society (LLS)
STOCK
Exchange:NASDAQ Stockholm
Ticker:BINV
Market Cap:$0.16B
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2a
Modalities:mAb, Oncolytic virus
Active Trials:5
Trial Phases:Phase 1: 3 | Phase 2: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:AstraZeneca (BI-1206 clinical supply), Merck (BI-1808 and BI-1607 combination studies), Transgene (BT-001 oncolytic virus), CASI Pharmaceuticals (BI-1206 licensing)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Martin Welschof - CEO
Andres McAllister - Chief Medical Officer
Björn Frendéus - Chief Scientific Officer
Board Members:Leonard Kruimer (Chairman), Laura Lassouw-Polman, Thomas Hecht, Nanna Lüneborg, Natalie Berner
LINKS
Website:bioinvent.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of BioInvent International AB and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with BioInvent International AB. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.